Clinical Trials Logo

Dry Eyes Chronic clinical trials

View clinical trials related to Dry Eyes Chronic.

Filter by:
  • None
  • Page 1

NCT ID: NCT06379685 Not yet recruiting - Dry Eye Clinical Trials

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Start date: September 30, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®.

NCT ID: NCT05169931 Withdrawn - Dry Eyes Chronic Clinical Trials

Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment

Start date: January 2022
Phase: Early Phase 1
Study type: Interventional

This prospective longitudinal study aims at evaluating the clinical efficacy of human amniotic fluid extract eye drops in the treatment of dry eye disease. 25 patients who are diagnosed with dry eye disease as defined by our criteria will be recruited from the cornea and dry eye clinic at Stein Eye Institute, UCLA. Pre-treatment baseline evaluations, 6 weeks, 12 weeks, and 24 weeks post treatment assessments will be performed by the principle investigator and co-investigator. All tests are considered non-invasive and are within the standard of practice in the evaluation for dry eye disease: (1) Ocular Surface Disease Index Questionnaire (OSDI); (2) Non-contact Tear Break-up Time (NITBUT); (3) Shirmer's test without anesthesia; (4) Ocular Surface Staining with Fluorescein and Lissamine green. Result of each test will be compared and analyzed to provide evidence of treatment efficacy. Treatment will be initiated for 12 weeks at a self-administered dose of one drop in both eyes two times per day. A follow-up of the study will be observed at the 24th week from the first day of treatment. All side effects and adverse events will be carefully observed and documented. Patients will be able to discontinue using the medication if they are not tolerating any side effects.

NCT ID: NCT03952481 Withdrawn - Dry Eye Clinical Trials

Effect of Lifitegrast 5% on Tear Film Markers

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.

NCT ID: NCT03089580 Completed - Dry Eyes Chronic Clinical Trials

Intense Pulsed Light Study for Dry Eye Disease

Start date: March 25, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy of intense pulsed light (IPL) therapy for the treatment of dry eye disease. One eye of the participant will be randomized to receive the IPL treatment.